Paclitaxel 80, Breast Cancer, adjuvant

Protocol-ID: 581 V1.2 (Short), PACL80, Breast Ca, adj.

Indication(s)

Breast Cancer; ICD-10 C50.-

Protocol classification

Classification: alternative
Intensity: Standard dose
Therapy phase:
Therapy intention: curative

Cycles

Cycle length 7 days, recommended cycles: 12

Protocol sequences

EC (EPIR90/CYCL600), Breast Ca, adj. (PID579) -|- PACL80, Breast Ca, adj. (PID581)

Risks

Emetogenicity (MASCC/ESMO): low (10-30%)
Neutropenia: low (<10%) °3-4: 2%
Febrile Neutropenia: low (<10%) °3-4: 1%
Infections: CTC AE °3-4: 3%
Fatigue: CTC AE °3-4: 3%
Neuropathy: CTC AE °2-4: 27%
Myalgias: CTC AE °3-4: 2%

Therapy

Day	Substance	Dosage	Appl.	Inf. time	Procedure
HYD Hydration: Balanced Crystalloid Solution
Access: peripheral venous
Hydration before, during, or after antitumor therapy
1	Balanced Crystalloid Solution	500 ml	i.v.	30 min	30 min before Paclitaxel (d1)

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
AP Allergy prophylaxis: Paclitaxel Allergy Prophylaxis
Access: peripheral venous
Dexamethasone, dimetinden maleate, cimetidine
1	Dexamethasone	20 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Paclitaxel (d1)
1	Dimetinden	4 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Paclitaxel (d1)
1	Cimetidine	300 mg	NaCl 0.9% 50 ml	i.v.	5 min	30 min before Paclitaxel (d1)

Day	Substance	Dosage	Solution	Appl.	Inf. time	Procedure
CTX Medical tumor therapy: Paclitaxel 80 mg/m²
Access: peripheral venous
weekly therapy
1	Paclitaxel	80 mg/m² BSA	NaCl 0.9% 250 ml	i.v.	60 min	Sequence

Concomitant therapy supplements

Dexamethasone for antiemesis is covered by dexamethasone of allergy prophylaxis.

References

Sparano JA, Weekly paclitaxel in the adjuvant treatment of breast cancer., N Engl J Med 2008 Apr 17;358(16):1663-71 [PMID]
De Laurentiis M, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials., J Clin Oncol 2008 Jan 1;26(1):44-53 [PMID]

Recommendations

08/2019: European Society for Medical Oncology
03/2023: National Comprehensive Cancer Network

The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 16.09.2023